World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 6.129

A REVIEW ON NOVEL THERAPEUTIC OPTIONS FOR THE TREATMENT OF TUBERCULOSIS IN THE COMMUNITY

Thanakanti Bhargavi[1*], A. Bharath Kumar[2], S. Kavya[3], Thota Srimannarayana[4], Shaik Mohammad Sohail[5], D. Jothieswari[6]

[1-5]Department of Pharmacy Practice, Sri Venkateswara College of Pharmacy, Chittoor, Andhra Pradesh.
[6]Department of Pharmaceutical Analysis, Sri Venkateswara College of Pharmacy, Chittoor, Andhra Pradesh.

Corresponding Author: Thanakanti Bhargavi
Department of Pharmacy Practice, Sri Venkateswara College of Pharmacy, Chittoor, Andhra Pradesh.

Article Received on 29/03/2022 **Article Revised on 19/04/2022** **Article Accepted on 09/05/2022**

ABSTRACT

Tuberculosis is a common cause of death and illness across the world. To reduce the worldwide impact of tuberculosis, early identification of the infection and early identification of therapeutic resistance is necessary. Although authorised diagnostic procedures like as culture, direct microscopy, bio-molecular assays, and whole genome sequencing are available, their general usage is typically limited due to prices, local resources, time restrictions, and operator efficiency. The susceptibility pattern of the isolate found determines which medication regimen should be used. The advancements in the treatment of tuberculosis lead to the development of novel therapeutic protocols including in the near future. By strengthening existing diagnostic and treating procedures, promoting prevention measures, increasing government commitment and greater funding, and accelerating research and innovation, the End-TB Strategy launched by WHO intends to significantly reduce the trouble of Tuberculosis on its way to global extinction. A variety of newer medications and therapeutic techniques are useful for the treatment of tuberculosis in the community.

KEYWORDS: Mycobacterium tuberculosis, Novel Diagnostic procedures, MDR-TB, Novel therapeutic protocols, END-TB strategy.

INTRODUCTION

Tuberculosis (TB) is the world's most contagious disease, with an expected 1.5 million deaths and 10 million new reported cases in recent times. Because of misdiagnosis and refusal to report to national tuberculosis programs, almost two million people with tuberculosis have been labeled "missing" despite the severity of the infection.[1] Non - communicable diseases, such as diabetes mellitus, are being examined as potential adverse outcomes for active tuberculosis in both poor and wealthy areas, generating new issues regarding primary prevention early identification.[2] In order to achieve the sustainable development Program to prevent tuberculosis, the World Health Organization's (WHO) End TB Strategy plans for the retrieval of these millions of missing persons (TB). This will involve the use of innovative testing procedures and improved test deployment strategies to achieve this objective. As the symptoms and screening procedures combine in the existing COVID-19 pandemic, so it is important to look at combining tuberculosis (TB) and (SARS-CoV 2) diagnostic M. tuberculosis (MTB) is expected to affect nearly 25% of the worldwide population, with a lifetime chance of having TB sickness of 5–10%. Rapid recognition of TB and quick assessment of treatment resistance is crucial for lowering the risk of tuberculosis.[3-5] In recent advances, we examine tuberculosis molecular diagnostics and layout the evolving picture and the fundamentals of ongoing and prospective difficulties in diagnostic purposes, management, and control. Other research articles for advancements in biomarker-based techniques for active and latent TB detection are suggested to viewers.[6-7]

Diagnosis

If one of four indicative complaints (persistent fever, cough for a period of 14 days or more, nocturnal sweats, and loss of weight) is mentioned tuberculosis (TB) should be considered. Sociological considerations such as interaction with such an active TB patient and/or exposure to those other factors associated with TB transmission or recurrence must also be thoroughly assessed.[8] Diagnosis of chronic diseases, such as type-2 diabetes, should be given special care since they may develop milder symptoms that are frequently misconstrued as being connected to their actual pathology. The presence of the etiological factor (Mycobacterium tuberculosis, MTB) in an acceptable

biological matrix is required to validate the identification of tuberculosis.[9]

Line Probe Assay: Line Probe Assay is a polymerase chain reaction-based swift method developed by India's Revised National Tuberculosis Control Programme (RNTCP) to recognize Mycobacterium tuberculosis complex along with a therapeutic response to rifampicin and isoniazid. In appropriate settings, it is utilized to diagnose drug-resistant tuberculosis.[10-11] LPA tests only phlegm that really is acid-fast bacilli (AFB) smear-positive.

Procedure: The Deoxyribonucleic Acid strip was taken out of the tube and labeled with the sample numbers. Then it was inserted in each well, which had 20µl of the appropriate amplified DNA sample, with the colored section facing up. Well has been put in the incubator, and the hybridization operation began. In the incubator machine, hybridization happened after pre-warming the hybridization buffer to 45 °C in a water bath for 15 minutes (Hain Life Science GmbH, Nehren, Germany). Denaturing solution (20µl) was pipetted into each tray, followed by 1 ml of rinse solution per well and incubation for 1 minute. The well was taken and thoroughly washed with a rinsing liquid. Every well received 1µl of conjugate, which was then incubated for 30 minutes before being taken and rinsed with rinsing liquid. Next, one milliliter of substrates had been poured into each well and incubated for ten minutes before being rinsed two times with distilled H2O. These were allowed to dry before being inspected and analyzed using specific equipment as identified, resistant, susceptible, or ineligible for the disease-causing pathogen.

Gene Xpert MTB

Gene Xpert is a good diagnostic technique for detecting Mycobacterium Tuberculosis in the initial stages when a direct smear is negative, but also for detecting Rifampicin resistance in the initial phases.[12-13] It takes 2 to 6 weeks for MTBC to develop in regular cultures, and routine drug resistance testing can add another 3 weeks. But this test gives results in less than 2 hours. The data supplied by the Xpert MTB/RIF test assists in the selection of therapy protocols and also the rapid decision-making process for disease management.[14]

Procedure: The person with probable tuberculosis is given a phlegm sample. The phlegm is combined with the assay's solution, and a cartridge carrying this combination is loaded into the GeneXpert machine. After this stage ahead, all procedure is automated. The Xpert MTB/RIF test results show if MTBC was found there in sample. In some cases, the results are "invalid," requiring that the test to be redone. If MTBC was found, the data will indicate whether RIF resistance was found to be Detected, undetected, or indeterminate. Irrespective of the Xpert MTB/RIF findings, patients samples must be cultured for mycobacterial isolates to be accessible for medication susceptibility testing and sequencing.

Advantages: 1. The results are readily available, and 2. To conduct the test, just basic technical knowledge is necessary. Furthermore, the Xpert MTB/RIF test can detect multidrug-resistant tuberculosis in a timely manner (MDR TB).

Loop-Mediated Isothermal Amplification (TB-LAMP)

Eiken Chemical Company Ltd (Tokyo, Japan) designed a commercial molecular test Loopamp MTBC Detection Kit for the identification of Mycobacterium tuberculosis complex relies on loop-mediated isothermal amplification (TB-LAMP) that depends on auto cycling strand displacement DNA synthesis by Bst DNA polymerase.[15-20] TB-LAMP is a mechanical assessment that takes just beneath 60 minutes to complete and so can be viewed with the human eye in UV irradiation. It is also used as a follow-up examination to microscopy in adults having clinical manifestations of pulmonary tuberculosis, particularly if extensive evaluation of phlegm smear-negative material is required. LAMP has the below-mentioned features: (i) All reactions can be conducted under ambient temperature [60 to 65°C] by utilizing a single type of enzyme.(ii) the significance of the reaction is immense since this uses 4 primers recognizing 6 different regions on the target DNA (iii) Amplification can be done in less duration than PCR amplification as there is no time loss caused by thermal cycling (iv) it generates massive volumes of amplicon and allows simplification.

Truenattest: Truenat is a novel chip-based, authentic PCR test which identifies tubercle bacteria in sputum samples in about 60minutes.[21-23] When a result is obtained as positive, a "add-on" chip is utilised to identify Rifampicin resistance, which adds additional 60 minutes of testing period. The test is organised and operate on the battery-powered Truelab system, which consists of sample preparation machine (a machine for extracting and purifying DNA from samples collected) as well as the PCR analyser tool, which is available in 1-, 2, or 4-module configurations, with the latter capable of screening 4 samples at about the same time.Truenat may be useful in outlying patient care environments, such as Designated microscopy centres (DMCs) and primary healthcare centres in India, because of its mobility. Truenat, if utilised as a point-of-care (POC) test in primary care settings, has the potential to boost therapy commencement by lowering wait period for test results as well as the requirement for laboratory referrals.[24-25] Truenat, which is already available in India, is positioned as a far more economical alternate option to Xpert, which is also manufactured in India. Materials developed and manufactured inside a country with a strong Incidence may be easier and faster to expand in the same country than materials produced in some other country, because governments seem to have a degree of

purchase, information from locally run study results will have acquired, and distribution network and regulatory issues are easier to resolve.True lab, which is available in Uno-, Duo-, and Quattro-throughput configurations, was meant to be "robust" with a particulate filter and the ability to operate in temperatures as high as 30°C, however, its many micro pipetting processes demand the use of a professional expert.The WHO Consolidated Guidelines on Molecular Diagnostics for 2020 propose utilizing Truenat MTB or MTB Plus as the first screening test for tuberculosis in children and adults with clinical manifestations of pulmonary tuberculosis instead of smear microscopy. In terms of Drug Susceptibility Testing [DST], this may be utilized as a first check for rifampicin resistance instead of phenotypic DST. This is likewise a conditional proposal, given there is very little confidence of evidence supporting test accuracy.[26-28]

Centralized diagnostic tests-High throughput solutions

Nucleic acid amplification tests [NAATs] for tb screening and medication resistance assessment were created and are now being evaluated by the WHO. Such nearly fully automatic tests are all designed for usage in tertiary laboratories. A WHO technical expert panel conference in 2019 concluded that the success of the centralized assays for identifying INH and RIF resistance was comparable to LPA and that Realtime MTB, Cobas MTB, and Max MDR-TB worked equivalent to Xpert MTB/RIF for Tuberculosis screening.[29-30] For time being, such tests are exclusively suggested to be used in operational research, with a WHO evaluation of wider usage due.

Realtime MTB

Multinodal NAAT has a limit of detection (LOD) of 17 CFU/ml that specifically destines MTB IS6100 as well as PAB genes. The Abbott m2000 platform can directly inhibit and evaluate up to 96 respiratory samples each batch.

FluoroType MTB

Sample disinfection, processing, and DNA extraction should be done manually which takes half an hour. The full procedure requires four hours to complete. It is a semiautomatic assay done on the Hain Fluorocycler platform.[31-32]

Max MDR-TB test

Aims at the 16S rRNA gene. Prior to separation and amplification by this test, about 24 samples are physically sterilized and processed. The overall duration from start to end is four hours.[33] Because of its excellent predictive quality and capacity to analyze huge data sets concurrently, centralized TB tests seem intriguing, and their automatic feature decreases the risk of hospital personnel including experimental professionals coming into touch with infected material. Thecentralized assay product lineup is fairly robust, and the respective platforms are now undergoing regulatory review.[34] All platforms now include testing for MDR-TB and XDR-TB, which will expand the number of possibilities available in the coming days. Carry-over contamination is already a possibility with these tests; thus, quality assurance is essential. Furthermore, the expenses of any of these investigations haven't been publicly disclosed, and there are no discounted or concessional billing plans. Moreover, because of their centralized position, these are not available where patients initially appear for treatment, hence sample movement is a must. For these assays to provide an effect, effective procedures for transmitting test findings to patients and clinicians should be in position.[33-34]

NEXT-Generation Sequencing: Next-generation sequencing (NGS) is becoming regarded as a potential alternative for extensive DST for tuberculosis (TB) since it gives findings considerably quicker than classic phenotypic culture or culture-based testing.[35-36] In contrast to LPA, which can only identify probe-specific targets, these may offer specific and comprehensive sequence data for complete genomes, as with whole-genome sequencing (WGS), or multiple gene areas of interest, as with tailored NGS.[37]

Treatment

Disease elimination and prevention of long-term damage caused by the illness or an unfavorable impact of the medications being used are the main mottos of the treatment. Drug-sensitive tuberculosis (DS-TB) has been successfully treated in 85 percent of patients. As a result of research showing patient choice and expense of these medications, there's been a move to oral treatment regimens wherever feasible.[38-39] We must provide a regimen that contributes to the worldwide aim of TB elimination, in a way that also represents patients' interests and, as a result, increases patient medication adherence.

Current Treatment

Current treatment includes Rifampicin (RIF) Isoniazid (INH) Pyrazinamide (PZA) Ethambutol (EMB) Levofloxacin (LFX)/Moxifloxacin (MFX) Bedaquiline (BDQ) Linezolid (LZD) Clofazimine (CFZ) Cycloserine (CYS) Delamanid (DLM) Aminoglycosides (AMK, CAP, STR) Ethionamide (ETH)/Prothionamide (Pro) p-Aminosalicylic acid (PAS) Amoxicillin–Clavulanatewith Meropenem or Imipenem–Cilastatin.

DS-TB is typically treated for 6 monthsconsisting of 2 phases of therapy.one is 2months ofintensivephase [RIFAMPICIN+ISONIAZID+PYRAZINAMIDE+ETH AMBUTOL] and a maintenancephase or continuation phase of 4 months [RIFAMPICIN and ISONIAZID therapy].[40] Ethambutol can be discontinued if the sample is sensitive to rifampicin and isoniazid. If there is a cavity on the first chest X-RAY, significant sputum development at 2 months, or pyrazinamide cannot be utilized owing to monoresistance or pharmacological adverse effects, the

maintenance period must be increased to 7months [consider immune compromised patients].Undesirable results are most probably linked with high-gradesmear-positive (at least 3+) and are reliant on cavity size along with illness severity on X RAYS.[40-41]

MDR-TB
First Line: LFX/MFX with all 4 of: BDQ+ LZD+CFZ+CYS.

Second Line: Consider DLM/PZA/ETM/AMK/STR

Third Line
ETH/PRO/IMIPENEM-
Cilastatin/Clavulante *or* Meropenem/Clavulanateor PAS or High Dose INH.

INH-resistant TB
RIF+PZA+ETM+FLQ for 6 months (can discontinue PZA after 2 months; FLQ only required in patients with extensive disease, *i.e*., cavitary or bilateral infiltrates).

RR-TB: As per MDR-TB
Thenoteworthy difference is the lengthier period of therapy requiring medication combos which are frequently inadequately accepted. In addition, there is some disagreement between both major international advisory groups (the WHO and the combined ATS/CDC/ERS/IDSA clinical practice guideline) about optimal medication choice and periods. While the WHO advises thatonly 4 medications be used in the intense phase of therapy, the ATS/CDC/ERS/IDSA suggest that 5 drugs be utilized in this period. This recommendation was made by the ATS/CDC/ERS/IDSA based on better success rates in the 5-drug group. Furthermore, they propose that one of the medicines will have to be removed owing to toxic effects.[42] However, given the inconclusive threat variations in both groups, the WHO believes that four medications should be adequate if susceptibilities are recognized and no toxicity. Identical data support de-escalation to a maintenance phase of 3 0r 4 medicines. MDR-TB therapy has traditionally needed a total of 15–21 months.[42] Alternately, it allows for a reduced 9–12-month all-oral protocol for patients who have not had more than 1 month of therapy earlier with second-line medicines and have Fluoroquinolones resistance ruled out. Furthermore, patients should not have significantly extensive sickness.[43] This regimen consists of four months of six medications (FLQ, clofazimine (CFZ), ETH, PZA, and INH (high dosage), followed by five months of FLQ, CFZ, ETH, and PZA. During the first 6 months of this regimen, Bedaquiline [BDQ] is administered simultaneously. This provisional advice based on low confidence evidence was recommended because of higher success and compliance rates in comparison to shorter injectable-agent treatments.[43-44] (It should be noted that INH is employed irrespective of sensitivity state. At the moment, the WHO advises treating RR-TB in the same way as MDR-TB is treated. Because of varied patterns of drug resistance, pre-XDR- and XDR-TB are harder to cure and guidance from national and worldwide expert TB organizations should always be consulted prior to beginning therapy.

New Treatment: Regimes 4-month rifapentine (RFP) withMoxifloxacin[MFX] has recently been demonstrated to be equivalent to the existing conventional 6-month treatment, as evaluated by negative smear or culture after 12 months, with no rise in significant negative events.In comparison to the traditional 6-month regimen, the SimpliciTB group assessed a 4-month treatment plan consisting of Bedaquiline, Pteromalid, Moxifloxacin, and Pyrazinamide. This combination is uncertain to be advised as a first-line treatment for DS-TB, given the necessity to retain effective pharmacological alternatives for resistant patients.[45-48] The TRUNCATE-TB study is in the recruiting phase, with a 2-month regimen. This study will evaluate combos of 4–5 presently authorized oral anti-tuberculous drugs administered daily for 8 weeks, with the possibility of extending to 12 weeks.The RIFASHORT and ReDEFINe trials are assessing the risk-benefit ratio of increasing RIF dosages in DS-TB.[49-51]

2) Drug-resistant TB
a**) RR-TB**
The existing guidelines for RR-TB have been regarded as problematic. These extended treatments are expected to subject individuals with mono-resistance to unnecessary protracted and hazardous medication treatments, while also excluding the advantages of Isoniazid treatment.[52] BEAT TB is now enrolling participants to compare the effectiveness of 6 months of Bedaquiline, Linezolid [LZD], delamanid (DLM), Levofloxacin, and Clofazimine to current South African treatments[53]. The modified STREAM2 research is testing a short treatment for Rifampicin Resistant-TB and Multi-Drug Resistant-TB. Their 4 regimens are based on present WHO practice, a 40-week all-oral treatment, and an oral treatment plan for 28 weeks following an 8-week intensive regime that included Isoniazid and kanamycin.[54-55]

b) MDR-TB
The results of the NEXT study, which is finished in December 2020, are expected soon. This study compared 6–9 months of Linezolid, Bedaquiline, Levofloxacin, Pyrazinamide, Ethionamide, or Isoniazid (high dosage) to current treatment.[56-58]

c) **XDR-TB**
In line with WHO advice, this BPaL regimen can now be utilized in patients with Multi-Drug Resistant-TB under operational research settings.[59-62]

Directly Observed Therapy
For numerous years, directly observed therapy (DOT) seems to have been the global standard in the treatment of tuberculosis. Patients tend to cooperate if drug

consumption is seen numerous times each week, according to the theory. It should be used in Multidrug-resistant- or Extensively drug resistant-TB cases, or for patients having complicated or critical clinical management.[63-69]

Prophylaxis

Tuberculosis will definitely continue to be a problem for many years. We do, however, have an opportunity to save several of these people from developing the aggressive illness. Testing for active tuberculosis in populations at increased risk of getting the illness is still an expense and necessary part of the worldwide effort. Specific people should be screened using either the approved interferon-release tests (T-SPOT.TB and QuantiFERON-TB Gold In-Tube) or standard tuberculin skin examination. The WHO recommends that guidance and counseling be used when evaluating such assays, and warns that systematic errors are more common in the most severe groups.[70] A better healthcare strategy that aids in connection monitoring of symptomatic patients and proper intervention of connections would be other critical features of the improvement plans. Furthermore, before undertaking any preventative medication, it is critical to remove the existence of active tuberculosis illness. In instances wherethe patient is medication susceptible, the WHO now recommends 4 months of Rifampicin or 6–9 months of Isoniazid treatment. Three-month treatment with Isoniazid and rifampicin has been permitted, however, it is seldom utilized due to the risk of poisoning. Furthermore, as compared to 6 months of Isoniazid therapy, weekly Rifampicin and isoniazid for 90 days demonstrated equivalent effectiveness and harm, with greater levels of compliance to 6 months of Isoniazid therapy.[71] Furthermore, for HIV individuals, a 1-month treatment of Rifampicin/Isoniazid treatment was found to be equivalent to 9 months of Isoniazid monotherapy in preventing Tuberculosis.[72-76] This is yet to be approved.The same guidelines apply to Tuberculosis contacts of Drug sensitive-TB persons who show signs of Tuberculosis infection. The advice is for 6–12 months of Fluoroquinolone therapy, with or without an additional medication, for associates of multi-Drug resistant-TB individuals. Treatment with Ethambutol and Pyrazinamide should be explored if a Fluoroquinolone cannot be utilized owing to resistance in the affected individua.

Vaccination

Given the present incidence of tuberculosisand the lifelong risk of developing an active illness, it is critical that we safeguard coming generations from such a burden by completely stopping transmission. Scientists have been able to identify numerous possible targets with a function in vaccination thanks to a better knowledge of the cellular mechanisms involved in Mtb susceptibility and pathogenesis. The cellular immune response is key to theist to promote T-helper (Th1) responses while suppressing Th2 and regulatory T-cell responses.[77-80] Mycobacterium tuberculosis seems to have noticed such a need to adjust toward this hypo-inflammatory character because more recent strains had reduced latency and greater virulence than prior strains.[78] The only globally authorized Tuberculosis vaccine is BCG, which successfully reduces the incidence of serious paediatric Tuberculosis illness, with an 85 percent decrease in Tuberculosis meningitis and miliary Tuberculosis in children under the age of 10 years.

Vaccination can be categorized into preventive pre-exposure, preventive post-exposure, or therapeutic[81]. Vaccines can alternatively be classified according to their biochemical forms: live attenuated, inactivated, protein subunit, or recombinant.[82] With each of these forms, the aim is to target various cells or subcellular components of TB pathogenesis. Preclinical experiments have demonstrated that MTBVAC, a pre-exposure live attenuated vaccine, provides better protection against tuberculosis than BCG.[83-85]

This vaccine has the ability to alter T-cell immune responses and boost Th1 immunity, both of which are critical in the pathogenesis of tuberculosis.M72/AS01E can be another intriguing post-exposure option. It prevents pulmonary Tuberculosis in people previously diagnosed with Mycobacterium tuberculosis in 54% of patients, and so might be a potentially life-saving approach for one-fourth of the global total population. This vaccine, also known as Mtb72F, is made up of two immunogenic proteins that increase T-cell multiplication and the production of interferon.[86]

CONCLUSION

A concerted efforts needs to develop novel TB technology and treatments. It's likely that each patient's therapy will be based on their own protein bio-signatures, as well as the genetic expression of mutations in the Mtb variant they've been exposed to. The first approach in fighting tuberculosis is to think about the disease, because early recognition and therapy are critical for achieving the greatest results and reducing the danger of spreading to others. The main focus on worldwide TB eradication, we must continue to work closely and communicate our expertise on a worldwide platform to guarantee that each patient is receiving the care and support they need to combat their Tuberculosis diagnosis without suffering considerable morbidity.

Conflicts of interest statement

The authors declare that they have no conflicts of interest.

REFERENCES

1. World Health Organization. Global tuberculosis report. World Health Organization, Geneva, Switzerland, 2019.

2. Creswell, J. et al. Tuberculosis and non-communicable diseases: neglected links and missed opportunities. Eur. Respir. J., 2011; 37: 1269–1282.
3. Gill CM, Dolan L, Piggott LM, McLaughlin AM. New developments in tuberculosis diagnosis and treatment. Breathe, 2022 Mar 1; 18(1).
4. MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM. A systematic review of biomarkers to detect active tuberculosis. Nat Microbiol, 2019; 4: 748–758.
5. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clinical microbiology reviews, 2014 Jan; 27(1): 3-20.
6. Sulis G, Centis R, Sotgiu G, D'Ambrosio L, Pontali E, Spanevello A, Matteelli A, Zumla A, Migliori GB. Recent developments in the diagnosis and management of tuberculosis. NPJ primary care respiratory medicine, 2016 Nov 3; 26(1): 1-8.
7. Chaudhuri AD. Recent changes in guidelines on programmatic management of drug resistant tuberculosis in India 2019: a paradigm shift in tuberculosis control. The Journal of Association of Chest Physicians, 2020 Jul 1; 8(2): 53.
8. Desikan P, Panwalkar N, Mirza SB, Chaturvedi A, Ansari K, Varathe R, Chourey M, Kumar P, Pandey M. Line probe assay for detection of Mycobacterium tuberculosis complex: An experience from Central India. The Indian journal of medical research, 2017 Jan; 145(1): 70.
9. Pham TH, Peter J, Mello FC, Parraga T, Lan NT, Nabeta P, Valli E, Caceres T, Dheda K, Dorman SE, Hillemann D. Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. International journal of infectious diseases, 2018 Mar 1; 68: 44-9.
10. Mori, Y., K. Nagamine, N. Tomita, and T. Notomi. 2001. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem. Biophys. Res. Commun, 2001 Nov 23; 289:150-154.
11. Nagamine K, Kuzuhara Y, Notomi T. Isolation of single-stranded DNA from loop-mediated isothermal amplification products. Biochemical and biophysical research communications, 2002 Feb 1; 290(4): 1195-8.
12. Nagamine K, Watanabe K, Ohtsuka K, Hase T, Notomi T. Loop-mediated isothermal amplification reaction using a nondenatured template. Clinical chemistry, 2001 Sep 1; 47(9): 1742-3.
13. Nikam C, Kazi M, Nair C, Jaggannath M, M M, R V, et al. Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosis. Int J Mycobacteriology, 2014; 3: 205–210.
14. Nikam C, Jagannath M, Narayanan MM, Ramanabhiraman V, Kazi M, Shetty A, Rodrigues C. Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach. PloS one, 2013 Jan 21; 8(1): e51121.
15. Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, Rade K, Swaminathan S, Mayer KH. The tuberculosis cascade of care in India's public sector: a systematic review and meta-analysis. PLoS medicine, 2016Oct25; 13(10): e1002149.
16. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, Rodriguez W, Bassett IV. Diagnostic point-of-care tests in resource-limited settings. The Lancet infectious diseases, 2014 Mar 1; 14(3): 239-49.
17. Ahmed N, Hasnain SE. Molecular epidemiology of tuberculosis in India: Moving forward with a systems biology approach. Tuberculosis, 2011 Sep 1; 91(5): 407-13.
18. Kohli M, MacLean E, Pai M, Schumacher SG, Denkinger CM. Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. European Respiratory Journal, 2021 Feb 1; 57(2).
19. Hofmann-Thiel S, Hoffmann H. Evaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country. BMC infectious diseases, 2014 Dec; 14(1): 1-5.
20. Rocchetti TT, Silbert S, Gostnell A, Kubasek C, Widen R. Validation of a multiplex real-time PCR assay for detection of Mycobacterium spp., Mycobacterium tuberculosis complex, and Mycobacterium avium complex directly from clinical samples by use of the BD Max open system. Journal of Clinical Microbiology, 2016 Jun; 54(6): 1644-7.
21. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. The lancet, 2010 May 29; 375(9729): 1920-37
22. Lee RS, Pai M. Real-time sequencing of Mycobacterium tuberculosis: are we there yet?. Journal of clinical microbiology, 2017 May; 55(5): 1249-54.
23. Walker TM, Kohl TA, Omar SV, Hedge J, Elias CD, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. The Lancet infectious diseases, 2015 Oct 1; 15(10): 1193-202.
24. Mathers CD. History of global burden of disease assessment at the World Health Organization. Archives of Public Health, 2020 Dec; 78(1): 1-3.
25. Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Torrico MM, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ. MDR/XDR-TB management of patients and contacts:

Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020 Mar 1; 92: S15-25.
26. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM. Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clinical infectious diseases, 2016 Oct 1; 63(7): e147-95.
27. Imperial MZ, Nahid P, Phillips PP, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature medicine, 2018 Nov; 24(11): 1708-15.
28. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. American journal of respiratory and critical care medicine, 2019 Nov 15; 200(10): e93-142.
29. Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegia M, Jaramillo E, Zignol M, Kasaeva T. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. European Respiratory Journal, 2021 Jun 1; 57(6).
30. Dorman SE, Nahid P, Kurbatova EV, Phillips PP, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HT, Hakim J, Johnson JL. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. New England Journal of Medicine, 2021 May 6; 384(18): 1705-18.
31. Prasad R, Gupta N, Banka A. Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. Lung India: official organ of Indian chest society, 2018 Jan; 35(1): 78.
32. Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine, 2018 Sep 1; 198(5): 657-66.
33. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. American journal of respiratory and critical care medicine, 2010 Sep 1; 182(5): 684-92.
34. Tian JH, Lu ZX, Bachmann MO, Song FJ. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. The International journal of tuberculosis and lung disease, 2014 Sep 1; 18(9): 1092-8.
35. Parums DV. Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis. Medical science monitor: international medical journal of experimental and clinical research, 2021; 27: e934292-1.
36. Story A, Garfein RS, Hayward A, Rusovich V, Dadu A, Soltan V, Oprunenco A, Collins K, Sarin R, Quraishi S, Sharma M. Monitoring therapy adherence of tuberculosis patients by using video-enabled electronic devices. Emerging infectious diseases, 2016 Mar; 22(3): 538.
37. Story A, Aldridge RW, Smith CM, Garber E, Hall J, Ferenando G, Possas L, Hemming S, Wurie F, Luchenski S, Abubakar I. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. The Lancet, 2019 Mar 23; 393(10177): 1216-24.
38. Gill CM, Dolan L, Piggott LM, McLaughlin AM. New developments in tuberculosis diagnosis and treatment. Breathe, 2022 Mar 1; 18(1).
39. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization, 2018. Google Scholar
40. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. New England Journal of Medicine, 2019 Mar 14; 380(11): 1001-11.
41. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures. PLoS medicine, 2019 Apr 23; 16(4): e1002786.
42. Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. European Respiratory Journal, 2020 Mar 1; 55(3).
43. Li Z, Hu J, Liu P, Cui D, Di H, Wu S. Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB. Scientific Reports, 2021 Jul 15; 11(1): 1-2.
44. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. The Lancet Infectious Diseases, 2021 Mar 1; 21(3): 354-65.
45. Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Human vaccines & immunotherapeutics, 2018 Jul 3; 14(7): 1697-716.
46. Gagneux S. Host–pathogen coevolution in human tuberculosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012 Mar 19; 367(1590): 850-9.

47. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, Sterne JA. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinical infectious diseases, 2014 Feb 15; 58(4): 470-80.
48. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proceedings of the National Academy of Sciences, 2012 Oct 23; 109(43): 17537-42.
49. Fatima S, Kumari A, Das G, Dwivedi VP. Tuberculosis vaccine: A journey from BCG to present. Life sciences, 2020 Jul 1; 252: 117594.
50. Whitlow E, Mustafa AS, Hanif SN. An overview of the development of new vaccines for tuberculosis. Vaccines, 2020 Dec; 8(4): 586.
51. Gonzalo-Asensio J, Marinova D, Martin C, Aguilo N. MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic. Frontiers in immunology, 2017 Dec 15; 8: 1803.
52. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, Grode L, Kaufmann SH. The recombinant Bacille Calmette–Guérin vaccine VPM1002: ready for clinical efficacy testing. Frontiers in immunology, 2017 Sep 19; 8: 1147.
53. Ottenhoff TH. A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. The New England Journal of Medicine, 2020 Apr 1; 382(16): 1576-7.
54. Nabavinia MS, Nasab MN, Meshkat Z, Derakhshan M, Khaje-Karamadini M. Construction of an expression vector containing Mtb72F of mycobacterium tuberculosis. Cell Journal (Yakhteh), 2012; 14(1): 61.
55. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000; 405(6789): 962–6.
56. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006; 3(11): e466.
57. Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem, 2011; 3(11): 1427–54.
58. Tasneen R, Tyagi S, Williams K, Grosset J. Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother, 2008; 52(10): 3664–8.
59. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother, 2010; 54(8): 3402–7.
60. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012; 366(23): 2151–60.
61. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother, 2011; 55(12): 5485–92.
62. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother, 2012; 56(6): 3114–20.
63. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012; 380(9846): 986–93.
64. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med, 2008; 178(11): 1180–5.
65. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012; 367(16): 1508–18.
66. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci., 2011; 1241: 48–70.
67. Protopopova M, Hanrahan C, Nikonenko B, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother, 2005; 56(5): 968–74.
68. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother, 2007; 51(4): 1563–5.
69. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother, 2010; 54(7): 2840–6.
70. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis., 1998; 26(4): 874–7.
71. Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis., 2001; 33(6): 466–9.
72. Payen MC, De Wit S, Martin C, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis, 2012; 16(4): 558–60.

73. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis, 2012; 16(8): 1005–14.
74. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol, 2007; 103(3-5): 793–8.
75. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis, 2013; 13(1): 27–35.
76. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med, 2004; 170(10): 1131–4.
77. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med, 2004; 169(3): 421–6.
78. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med, 2006; 174(3): 331–8.
79. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med, 2009; 180(3): 273–80.
80. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet, 2009; 373(9670): 1183–9.
81. Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother, 2007; 51(8): 2861–6.
82. Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother, 2008; 52(11): 4037–42.
83. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis., 2003; 37(11): 1448–52.
84. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005; 307(5707): 223–7.
85. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem, 2008; 283(37): 25273–80.
86. Rao SP, Alonso S, Rand L, Dick T, Pethe K, et al. The proton motive force is required for maintaining ATP homeostasis and viability of hypoxic, non replicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA, 2008; 105(33): 11945–50.